Neuca

Neuca Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Neuca (NEU.WA) as of Oct 21, 2026 is -61.77. In the previous year, Cash Conversion Cycle (CCC) was -53.49 — a change of 15.47% (lower).

Cash Conversion Cycle

-61.77

YoY

15.47%

Last updated:

Cash Conversion Cycle (CCC) of Neuca is 2025 -61.77 . Cash Conversion Cycle (CCC) of Neuca was 2024 -53.49 . It decreases by 15.47% lower compared to the previous year.

The Neuca Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
-59.15 PLN
Jan 1, 2019
-14.36 PLN
Jan 1, 2020
-54.90 PLN
Jan 1, 2021
-57.74 PLN
Jan 1, 2022
-65.75 PLN
Jan 1, 2023
-60.79 PLN
Jan 1, 2024
-53.49 PLN
Jan 1, 2025
-61.77 PLN
The Neuca Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-61.77+15.47%
-53.49-12.00%
-60.79-7.55%
-65.75+13.87%
-57.74+5.17%
-54.90+282.24%
-14.36-75.72%
-59.15+497.85%
-9.89+14.24%
-8.66-81.88%
-47.81+2,437.99%
-1.88—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuca Stock analysis

What does Neuca do? NEUCA SA generates revenue through the wholesale distribution of pharmaceutical products to pharmacies, leveraging its extensive network in the health market. The company also produces and sells its own branded drugs, supplements, and cosmetics, while offering clinical trials, telemedicine services, and IT solutions tailored for healthcare providers. Its e-commerce platform further supports the healthcare industry by enabling digital transactions for medical products and services. The primary buyers include pharmacies, healthcare institutions, and consumers seeking health-related products through online channels. NEUCA SA's business model integrates multiple revenue streams within the health sector, with a focus on both physical and digital distribution. The firm's own-brand products, such as pharmaceuticals and cosmetics, are sold directly to end-users and retail partners, while its IT solutions and telemedicine services target healthcare organizations. Clinical trials represent another key segment, attracting partnerships with research institutions and pharmaceutical firms. The company's operational scope spans from production to distribution, ensuring a comprehensive approach to healthcare market needs. The company's revenue is driven by its diversified portfolio, including drug distribution, branded product sales, and specialized services like telemedicine and clinical trials. Pharmacies remain the core customer segment for its wholesale operations, while e-commerce and IT solutions cater to a broader audience of healthcare providers and consumers. NEUCA SA's strategic positioning in the health market allows it to capitalize on multiple growth areas without relying on a single revenue source. Neuca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuca stock

Cash Conversion Cycle (CCC) of Neuca is -61.77 in 2025.

Cash Conversion Cycle (CCC) of Neuca changed from -53.49 to -61.77, representing a 15.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Neuca since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Neuca with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Neuca

All Key Metrics — Neuca